AI Transforms Clinical Trial Design and Decentralized Trials, But Recruitment Challenges Persist

Artificial intelligence is poised to fundamentally transform the decentralized clinical trials (DCT) landscape, addressing critical inefficiencies that have plagued the industry for decades, according to a new analysis from BCC Research. The analysis examines how AI technologies are revolutionizing patient recruitment, retention, and data quality management while attracting significant venture capital investment across the sector.

Leading DCT platforms have raised over $650 million in recent funding rounds. Medable secured $506.6 million in total funding, including a $304 million Series D in 2021, while Lindus Health raised $55 million in Series B funding in 2025. Top 20 pharmaceutical companies report a threefold acceleration in patient recruitment and a 40% reduction in screen-failure rates using AI-powered patient identification and matching systems, addressing the critical issue where 80% of studies fail to meet enrollment deadlines using traditional methods. AI-enabled risk-based quality management (RBQM) frameworks are reducing source data verification efforts by focusing on critical data points, and automated anomaly detection systems improve data integrity across multiple distributed sites and devices. Predictive analytics and engagement scoring systems are significantly reducing patient dropout rates in remote decentralized studies. Emerging technology convergence includes computer vision for remote protocol adherence, natural language processing for trial matching, and federated learning for privacy-preserving AI models. Key players establishing dominant positions include Medable, Science 37, Lindus Health, Curebase, Castor, Deep 6 AI, Veeva Systems, IQVIA, and Medidata. Traditional manual recruitment processes cause $1 million per month delays in studies, creating compelling economic incentives for AI-powered alternatives.

According to the CEO of Trialynx, an AI-powered clinical trial platform, clinical trial design has entered a new era. Up until 2024, the industry relied on manually copying and pasting protocols from previous trials, leading to an incredibly high failure rate, including missed end points, timeline overruns, and patient enrollment shortfalls. AI can now scrape massive data sets and look for end points in other clinical trials in the domain, or what other tests were done, providing predictive quality into protocols and planning. The CEO emphasized that failure rates can be reduced by putting more thought up front, using decentralized elements to make trials easier on patients and sites, and decreasing data burden, noting that the industry has been overcollecting data that often does not support the end points and objectives.

Lean trial design was highlighted as critical: patients should never be put through tests, visits, or questionnaires that do not directly support the trial's goals. An example was given of a clinical team that wanted to administer eight psychological questionnaires — about two hours of questionnaires — to patients, with questionable validity of the assessments. The CEO stressed the importance of considering the patient journey, including drive distance, the possibility of decentralized options, home visits, or online questionnaires, and ensuring patients are reimbursed correctly for their time. Sites often bear the brunt of poor planning and trial design, with decisions on which trials to take on based on operational impact such as coordinator workload and visit intensity.

However, there is a danger in assuming that an AI-optimized trial is automatically a recruitable trial. A protocol can be scientifically sound, statistically robust, and operationally well modelled, yet still struggle once it starts looking for real patients, real sites, and real coordinators. Recruitment problems are often baked in long before a trial launches, through inclusion and exclusion criteria, visit schedules, endpoint strategy, geography, site selection, and patient-facing burden. Optimization always depends on the question being asked: a design optimized for statistical power or regulatory confidence may not be optimized for patient participation. A narrower patient subgroup may improve scientific precision but reduce the recruitment pool; additional assessments may increase participant burden; more frequent visits may make the trial unrealistic for patients who work, travel, care for others, or live far from the site. Patients experience a trial as time, travel, uncertainty, procedures, disruption, and possible side effects, while sites experience it through feasibility questionnaires, competing workloads, staff capacity, and visit complexity.

Adaptive trial designs and simulation-based planning are also becoming essential, allowing sponsors to build flexibility into protocols and respond to real-world variability. By anticipating uncertainty early and adjusting designs as data emerges, sponsors can protect statistical integrity and improve the likelihood of achieving primary endpoints. Additionally, EHR-to-EDC integrations are reducing manual transcription and improving data accuracy, with AI increasingly used to support quality checks and monitoring under human oversight. Long-term scalability will depend on validation frameworks, regulatory alignment, and collaboration across sponsors, sites, and vendors. The functional-service provider model is seeing growing adoption, allowing sponsors to retain strategic oversight while leveraging CRO expertise to improve efficiency and resource allocation.